Yeah, sure. So PACE-C was a very similar trial to PACE-B, but with men with slightly more advanced prostate cancer, men who actually do need the addition of the hormone therapies for prostate cancer. So those men all received hormone therapy plus radiotherapy, and they were randomized in the study to either four weeks of treatment or just five days, similar to PACE-B. And what we’ve already shown and presented at ASTRO this year, in fact, was the two-year toxicity data, which looks very similar to PACE-B...
Yeah, sure. So PACE-C was a very similar trial to PACE-B, but with men with slightly more advanced prostate cancer, men who actually do need the addition of the hormone therapies for prostate cancer. So those men all received hormone therapy plus radiotherapy, and they were randomized in the study to either four weeks of treatment or just five days, similar to PACE-B. And what we’ve already shown and presented at ASTRO this year, in fact, was the two-year toxicity data, which looks very similar to PACE-B. So we were initially worried that by treating these more advanced cancers, we might have to treat a slightly larger area that might cause more side effects. But thankfully, that didn’t seem to be the case. We saw the same pattern as PACE-B, so the men who have the shorter treatment do get more temporary bladder side effects around one to two years after treatment, but after that the side effects appear very well controlled, at least in PACE-B. So that has given us some encouragement that the treatment is very well tolerated, but of course we need to wait for the five-year cancer control outcomes from PACE-C, which are due in a couple of years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
